Tevogen Bio Holdings (TVGN) Share-based Compensation (2024 - 2026)

Tevogen Bio Holdings has reported Share-based Compensation for 3 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 65.51% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $10.8 million (down 45.64% YoY), and the FY2025 full-year result was $16.2 million, down 60.2% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.9 million, down from $2.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $26.3 million in Q1 2024, with the low at $1.9 million in Q1 2026.
• Historically, Share-based Compensation has averaged $6.3 million across 3 years, with a median of $3.3 million in 2024.
• The largest YoY upside for Share-based Compensation was 2.49% in 2025 against a maximum downside of 79.24% in 2025.
• Tevogen Bio Holdings' Share-based Compensation stood at $7.0 million in 2024, then tumbled by 64.86% to $2.4 million in 2025, then declined by 22.92% to $1.9 million in 2026.
• The last three Share-based Compensation figures came in at $1.9 million (Q1 2026), $2.4 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.